Is it safe for a woman in her 50s to remain on Depo-Provera (medroxyprogesterone acetate)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: December 6, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Depo-Provera Use in Women Over 50

Women in their 50s should generally discontinue Depo-Provera and transition to alternative contraception or discontinue contraception entirely once menopause is confirmed, as the risks of prolonged use (particularly bone mineral density loss) increase with age while the need for contraception diminishes as natural fertility declines.

Duration of Contraceptive Use

  • Contraception should be continued until menopause is confirmed (12 months without menstruation) or until age 50-55 years, as women over 44 still require contraceptive protection if pregnancy avoidance is desired 1, 2.

  • The median age of menopause is approximately 51 years in North America, though it can vary from 40 to 60 years 1.

  • No reliable laboratory tests exist to confirm definitive loss of fertility; follicle-stimulating hormone levels may not be accurate for this determination 1.

Key Safety Concerns for Women Over 50

Bone Mineral Density Loss

  • Long-term Depo-Provera use is associated with significant bone mineral density (BMD) reduction, particularly in the lumbar spine 3.

  • This bone loss is caused by estrogen deficiency induced by DMPA and can be arrested with estrogen replacement therapy 3.

  • While BMD losses stabilize by 5 years and are largely reversible after discontinuation, the concern is heightened in perimenopausal women who are already at risk for osteoporosis 4.

  • Women in their 50s approaching or entering menopause face compounded bone loss from both DMPA use and natural menopausal estrogen decline.

Age-Related Classification

  • The U.S. Medical Eligibility Criteria classifies Depo-Provera as Category 2 (benefits generally outweigh risks) for women over 45 years, indicating increased caution is warranted 4.

  • This contrasts with Category 1 classification for younger women (18-45 years), reflecting age-related concerns 4.

Recommended Approach

For Women Still Requiring Contraception

  • Transition to copper IUDs, levonorgestrel IUDs, or contraceptive implants, which are classified as Category 1 (no restrictions) for women over 40 and have more favorable safety profiles 1.

  • These long-acting reversible contraceptive methods avoid the bone density concerns associated with DMPA while providing highly effective contraception until menopause is confirmed 1.

For Women Approaching Menopause

  • Assess menstrual patterns carefully: If amenorrhea has been present for 12 consecutive months, menopause is confirmed and contraception can be discontinued 1, 2.

  • Be aware that DMPA itself causes amenorrhea in many users, making menopause assessment challenging 5, 6. Consider transitioning to a method that allows menstrual pattern monitoring.

  • If continuing DMPA temporarily, ensure adequate calcium and vitamin D supplementation with regular weight-bearing exercise, and avoid smoking and alcohol to maintain skeletal health 4.

Common Pitfalls to Avoid

  • Do not assume fertility has ended before confirmed menopause, as unintended pregnancy remains possible and carries higher maternal and fetal complication risks in advanced reproductive age 1.

  • Do not continue DMPA indefinitely without reassessing the risk-benefit ratio, particularly regarding cumulative bone density loss in perimenopausal women 4, 3.

  • Do not rely on amenorrhea alone to determine menopause in DMPA users, as the medication itself causes amenorrhea independent of menopausal status 5, 6.

References

Guideline

Contraception in Women Over 40

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Contraception for Smokers Over 40

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Depo Provera. Position paper on clinical use, effectiveness and side effects.

The British journal of family planning, 1999

Research

Long-term contraception with Depo-Provera: a clinical evaluation.

International journal of fertility, 1980

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.